Atorvastatin blocks increased l-type Ca2+ current and cell injury elicited by angiotensin II via inhibiting oxide stress

Acta Biochimica et Biophysica Sinica

Volumn 48, Issue 4, 2016, Pages 378-384

  Ma, Yanzhuo ^a   Kong, Lingfeng ^a,b   Qi, Shuying ^a   Wang, Dongmei ^a  

^a BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

angiotensin II; apoptosis; atorvastatin; L type Ca2+ current

Indexed keywords

ANGIOTENSIN II; ATORVASTATIN; CALCIUM CHANNEL L TYPE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM; NEWBORN; OXIDATIVE STRESS; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; ATORVASTATIN CALCIUM; CALCIUM CHANNELS, L-TYPE; CELL LINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

EID: 84964300634     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmw009     Document Type: Article

References (28)

1. Rugale C, Delbosc S, Mimran A, Jover B. Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. J Cardiovasc Pharmacol 2007, 50: 293-298.
2. Ozturk N, Yaras N, Ozmen A, Ozdemir S. Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart. J Bioenerg Biomembr 2013, 45: 343-352.
3. Seto SW, Au AL, Poon CC, Zhang Q, Li RW, Yeung JH, Kong SK, et al. Acute simvastatin inhibits K ATP channels of porcine coronary artery myocytes. PLoS One 2013, 8: e66404.
4. Seto SW, Au AL, Lam TY, Chim SS, Lee SM,Wan S, Tjiu DC, et al. Modulation by simvastatin of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine coronary artery smooth muscle cells. Br J Pharmacol 2007, 151: 987-997.
5. Su F, Shi M, Yan Z, Ou D, Li J, Lu Z, Zheng Q. Simvastatin modulates remodeling of Kv4.3 expression in rat hypertrophied cardiomyocytes. Int J Biol Sci 2012, 8: 236-248.
6. Plante I, Vigneault P, Drolet B, Turgeon J. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci 2012, 101: 868-878.
7. Ding C, Fu XH, He ZS, Chen HX, Xue L, Li JX. Cardioprotective effects of simvastatin on reversing electrical remodeling induced by myocardial ischemia-reperfusion in normocholesterolemic rabbits. Chin Med J 2008, 121: 551-556.
8. Laszlo R, Menzel KA, Bentz K, Schreiner B, Kettering K, Eick C, Schreieck J. Atorvastatin treatment affects atrial ion currents and their tachycardiainduced remodeling in rabbits. Life Sci 2010, 87: 507-513.
9. Tamargo J, Caballero R, Gomez R, Nunez L, Vaquero M, Delpon E. Lipid-lowering therapy with statins, a newapproach to antiarrhythmic therapy. Pharmacol Ther 2007, 114: 107-126.
10. Bergdahl A, Persson E, Hellstrand P, Sward K. Lovastatin induces relaxation and inhibits L-type Ca(2+) current in the rat basilar artery. Pharmacol Toxicol 2003, 93: 128-134.
11. Zhang M, Kho AL, Anilkumar N, Chibber R, Pagano PJ, Shah AM, Cave AC. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation 2006, 113: 1235-1243.
12. Zhou C, Ziegler C, Birder LA, Stewart AF, Levitan ES. Angiotensin II and stretch activate NADPH oxidase to destabilize cardiac Kv4.3 channel mRNA. Circ Res 2006, 98: 1040-1047.
13. Aiello EA, Cingolani HE. Angiotensin II stimulates cardiac L-type Ca(2+) current by a Ca(2+)-and protein kinase C-dependent mechanism. Am J Physiol Heart Circ Physiol 2001, 280: H1528-H1536.
14. Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M, Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003, 108: 1567-1574.
15. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM, Sorrentino S, et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007, 100: 894-903.
16. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.NEngl J Med 1992, 327: 669-677.
17. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349: 1893-1906.
18. Waring P. Redox active calcium ion channels and cell death. Arch Biochem Biophys 2005, 434: 33-42.
19. Pessah IN, Kim KH, FengW. Redox sensing properties of the ryanodine receptor complex. Front Biosci 2002, 7: a72-a79.
20. Bers DM. Cardiac excitation-contraction coupling. Nature 2002, 415: 198-205.
21. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008, 1: 62-73.
22. Wang MC, Collins RF, Ford RC, Berrow NS, Dolphin AC, Kitmitto A. The three-dimensional structure of the cardiac L-type voltage-gated calcium channel: comparison with the skeletal muscle form reveals a common architectural motif. J Biol Chem 2004, 279: 7159-7168.
23. Bodi I, Mikala G, Koch SE, Akhter SA, Schwartz A. The L-type calcium channel in the heart: the beat goes on. J Clin Invest 2005, 115: 3306-3317.
24. Treinys R, Jurevicius J. L-type Ca2+ channels in the heart: structure and regulation. Medicina 2008, 44: 491-499.
25. Qi XY, Yeh YH, Xiao L, Burstein B, Maguy A, Chartier D, Villeneuve LR, et al. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res 2008, 103: 845-854.
26. Deo SH, Fisher JP, Vianna LC, Kim A, Chockalingam A, Zimmerman MC, Zucker IH, et al. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol 2012, 303: H377-H385.
27. Chiu CZ, Wang BW, Shyu KG. Use of atorvastatin to inhibit hypoxia-induced myocardin expression. Eur J Clin Invest 2012, 42: 564-571.
28. Gray DF, Bundgaard H, Hansen PS, Buhagiar KA, Mihailidou AS, Jessup W, Kjeldsen K, et al. HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density. Cardiovasc Res 2000, 47: 329-335.